BridgeBio Oncology's chief medical officer to resign effective January 2027
Yong Ben, M.D., M.B.A. gave notice on October 30, 2026 that he will step down as Chief Medical and Development Officer, with the resignation effective January 8, 2027.
BridgeBio Oncology Therapeutics, Inc. disclosed in an 8-K filing that on October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc., effective January 8, 2027.1
The company stated that Dr. Ben's resignation was not due to any disagreement regarding the operations, policies or practices of the Company.1
The filing was signed on November 5, 2026 by Pedro J. Beltran, Ph.D., identified as Chief Executive Officer1 of the company. October 30, 2026 is listed as the date of the earliest event reported in the filing, while November 5, 2026 is the date the document itself was signed.
The 8-K was filed under Item 5.02, covering departures, elections, and appointments of directors or certain officers. BridgeBio Oncology Therapeutics trades on The Nasdaq Global Market under the ticker symbol BBOT, as listed in the filing's cover page.
The filing does not disclose who, if anyone, will succeed Dr. Ben in the Chief Medical and Development Officer role, nor does it provide further detail on his planned departure beyond the effective date.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.